Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations
oleh: Mélissanne de Wispelaere, Guangyan Du, Katherine A. Donovan, Tinghu Zhang, Nicholas A. Eleuteri, Jingting C. Yuan, Joann Kalabathula, Radosław P. Nowak, Eric S. Fischer, Nathanael S. Gray, Priscilla L. Yang
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2019-08-01 |
Deskripsi
Targeted protein degradation (TPD) is a promising strategy for drug development. In this proof-of-concept study, the authors use telaprevir, which binds hepatitis C virus (HCV) NS3/4A protease, to target the protease for protein degradation, and show inhibition of wildtype as well as drug resistant HCV.